Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Eur J Cancer ; 178: 150-161, 2023 01.
Article de Anglais | MEDLINE | ID: mdl-36442460

RÉSUMÉ

BACKGROUND: Personalised radiotherapy can improve treatment outcomes of patients with head and neck cancer (HNC), where currently a 'one-dose-fits-all' approach is the standard. The aim was to establish individualised outcome prediction based on multi-institutional international 'big-data' to facilitate risk-based stratification of patients with HNC. METHODS: The data of 4611 HNC radiotherapy patients from three academic cancer centres were split into four cohorts: a training (n = 2241), independent test (n = 786), and external validation cohorts 1 (n = 1087) and 2 (n = 497). Tumour- and patient-related clinical variables were considered in a machine learning pipeline to predict overall survival (primary end-point) and local and regional tumour control (secondary end-points); serially, imaging features were considered for optional model improvement. Finally, patients were stratified into high-, intermediate-, and low-risk groups. RESULTS: Performance score, AJCC8thstage, pack-years, and Age were identified as predictors for overall survival, demonstrating good performance in both the training cohort (c-index = 0.72 [95% CI, 0.66-0.77]) and in all three validation cohorts (c-indices: 0.76 [0.69-0.83], 0.73 [0.68-0.77], and 0.75 [0.68-0.80]). Excellent stratification of patients with HNC into high, intermediate, and low mortality risk was achieved; with 5-year overall survival rates of 17-46% for the high-risk group compared to 92-98% for the low-risk group. The addition of morphological image feature further improved the performance (c-index = 0.73 [0.64-0.81]). These models are integrated in a clinic-ready interactive web interface: https://uic-evl.github.io/hnc-predictor/ CONCLUSIONS: Robust model-based prediction was able to stratify patients with HNC in distinct high, intermediate, and low mortality risk groups. This can effectively be capitalised for personalised radiotherapy, e.g., for tumour radiation dose escalation/de-escalation.


Sujet(s)
Tumeurs de la tête et du cou , Humains , Tumeurs de la tête et du cou/radiothérapie , Pronostic , Appréciation des risques/méthodes , Facteurs de risque , Résultat thérapeutique
2.
IEEE Trans Vis Comput Graph ; 29(1): 798-808, 2023 Jan.
Article de Anglais | MEDLINE | ID: mdl-36166562

RÉSUMÉ

Contrails are condensation trails generated from emitted particles by aircraft engines, which perturb Earth's radiation budget. Simulation modeling is used to interpret the formation and development of contrails. These simulations are computationally intensive and rely on high-performance computing solutions, and the contrail structures are not well defined. We propose a visual computing system to assist in defining contrails and their characteristics, as well as in the analysis of parameters for computer-generated aircraft engine simulations. The back-end of our system leverages a contrail-formation criterion and clustering methods to detect contrails' shape and evolution and identify similar simulation runs. The front-end system helps analyze contrails and their parameters across multiple simulation runs. The evaluation with domain experts shows this approach successfully aids in contrail data investigation.

3.
IEEE Trans Vis Comput Graph ; 28(1): 151-161, 2022 01.
Article de Anglais | MEDLINE | ID: mdl-34591766

RÉSUMÉ

Although cancer patients survive years after oncologic therapy, they are plagued with long-lasting or permanent residual symptoms, whose severity, rate of development, and resolution after treatment vary largely between survivors. The analysis and interpretation of symptoms is complicated by their partial co-occurrence, variability across populations and across time, and, in the case of cancers that use radiotherapy, by further symptom dependency on the tumor location and prescribed treatment. We describe THALIS, an environment for visual analysis and knowledge discovery from cancer therapy symptom data, developed in close collaboration with oncology experts. Our approach leverages unsupervised machine learning methodology over cohorts of patients, and, in conjunction with custom visual encodings and interactions, provides context for new patients based on patients with similar diagnostic features and symptom evolution. We evaluate this approach on data collected from a cohort of head and neck cancer patients. Feedback from our clinician collaborators indicates that THALIS supports knowledge discovery beyond the limits of machines or humans alone, and that it serves as a valuable tool in both the clinic and symptom research.


Sujet(s)
Infographie , Tumeurs de la tête et du cou , Humains
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE